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Background and Objective: Parkinson’s disease (PD) is a common
neurodegenerative disease. Previous studies have demonstrated the effect of
cell‐based therapies, but their clinical efficacy and safety have not been
evaluated. This review protocol aimed to systematically evaluate the effect of
stem cell therapy in patients with PD and to develop an evidence base for
guiding policy and practice.
Methods: PubMed, Embase, MedlinePlus, The Lancet and Brain were
searched over the period January 2001 to October 2019. The keywords used
for searching were “Parkinson’s disease” and “cell therapy” and
“mesenchymal stem cells” and “embryonic stem cells” and “brain‐derived
neural stem cells” and “neural progenitor cells”. The Preferred Reporting
Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement and a
measurement tool, Assessment of Multiple Systematic Reviews (AMSTAR),
to assess systematic reviews were used to assess the reporting quality and
methodological quality. Data extracted included study details, participant
details, intervention details and outcome.
Results: Nine valid research papers were screened out by systematic analysis.
These nine studies were carried out in different countries, with different
populations and cell types. According to evaluation methods used, all of the
transplantation therapies reported can improve the symptoms of PD patients.
Conclusions: Cell transplantation is a potential treatment option for PD.
More studies with strict study design, larger sample sizes, and longer
follow‐up are needed in the future.

© The authors 2020. This article
is published with open access at
http://jnr.tsinghuajournals.com
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Introduction

Parkinson’s disease (PD) is a prevalent neuro‐

degenerative disease which affects 1%–3% of the
population over 60 years of age. The main
pathological characteristic of PD is the dysfunc‐
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tion or loss of dopamine (DA) neurons in the
substantia nigra, which leads to a motor
disorder, such as tremor, rigidity, bradykinesia,
or postural instability [1, 2]. Treatment strategies
for PD patients include traditional treatments,
such as dopamine medication or surgical
procedures, and novel methods, such as alterna‐
tive therapies, Chinese medicine, optogenetics
and cell transplantation.
The traditional treatments enhance dopamine
levels by using levodopa, a dopamine precursor,
to increase dopamine production or carbidopa
to reduce dopamine degradation in the
peripheral blood. Long‐term treatment with
levodopa or carbidopa can be accompanied by
the development of both behavioral and motor
complications, such as dyskinesia [3]. Surgical
procedures include deep brain stimulation (DBS)
and pallidotomy, which involves small destruc‐
tion of the subthalamic nucleus to stimulate the
dysfunctional neurons [4]. All of these strategies
are available for the symptomatic treatment of
PD, but cannot prevent progression of the disease.
Chinese medicine can effectively relieve the
symptoms of PD. In particular, acupuncture is
widely used in PD treatment [5]. Optogenetics
has provided the opportunity to modulate
specific target neurons. Since optogenetics can
individually control specific neurons in freely
moving animals, it could be proposed to restore
neural circuit function to PD [6]. Recently
cell‐based therapies have gained prominence, as
promising treatments to replace the missing
dopamine neurons and restore the motor
function of PD patients [7–9]. Open clinical trials
have demonstrated that mesenchymal stromal
cells and embryonic stem cells (ESCs) may
reduce neuronal cell loss and benefit PD
patients [10]. The Unified Parkinson’s Disease
Rating Scale (UPDRS) has shown a steady
improvement in patients and their symptoms,
including facial expression, gait, and freezing

episodes. No tumor formation, transplantation
complication, severe hemorrhage, infection or
severe immune rejection was reported, suggesting
the efficacy and safety of human stem cells. One
study reported that grafted nigral neurons were
found to have Lewy body‐like inclusions 14 years
after transplantation, which suggests that PD can
affect grafted cells in the striatum [7], and the
clinical benefits induced by grafts were gradually
lost following transplantation [11]. All of these
studies suggest that the effect and safety of cell
therapies should be evaluated, whilst monitoring
the long‐term and side effects.
Cell‐based therapies have gained attention in
recent years; however, their clinical safety,
feasibility and efficacy are still unknown as only
a few relevant case studies have been reported.
Therefore, a systematic review is needed. In this
review, we systematically evaluate the efficacy
of cell transplantations in PD treatment. A
comprehensive and systematic understanding
may help to develop the evidence base for PD
therapies to guide policy and benefit patients in
clinical practice.

2
2.1

Methods
Study inclusion and exclusion criteria

The inclusion criteria were (1) formal published
studies; and (2) human study. No restrictions on
language or publication status were applied. The
exclusion criteria were (1) article types including
conference abstract, review, case, editorial, and
letter; (2) repeated publications; and (3) studies
with inadequate data and unavailability of full‐
text articles, and ongoing trials.
2.2

Data sources and search strategy

We searched the references systematically in
several major meta‐databases. Pubmed, Embase
and MedlinePlus were searched over the period
from January 2001 to October 2019. Other
Journal of Neurorestoratology
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resources, including unpublished grey literature
and published literature from the journals The
Lancet and Bain, were also searched by screening
reference lists. The keywords used for searching
were “Parkinson’s disease” and “cell therapy”
and “mesenchymal stem cells” and “embryonic
stem cells” and “brain‐derived neural stem
cells” and “neural progenitor cells”. Our search
terms for Pubmed were (ʺParkinson diseaseʺ
[Mesh]) OR (idiopathic Parkinsonʹs disease
[Title/Abstract]) OR (Lewy body Parkinsonʹs
disease [Title/Abstract]) OR (paralysis agitans
[Title/Abstract]) AND (ʺstem cellsʺ [Mesh]) OR
(progenitor cells [Title/Abstract]). In addition,
we did a round of manual search of the
references from the included studies.
2.3

Data extraction and management

The Preferred Reporting Items for Systematic
Reviews and Meta‐Analyses (PRISMA) statement
and a measurement tool, Assessment of
Multiple Systematic Reviews (AMSTAR), were
used to assess the reporting quality and

Fig. 1

Flow diagram of literature and screen strategy.
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methodological quality. The data extracted
included study details (publication year,
country), participant details (demographics,
stem cell species), intervention details (such as
indicators, diagnostic tools), and outcome.
2.4

Selection of studies

Two investigators carried out the database
search independently, based on the same criteria.
Two investigators further worked indepen‐
dently to assess each study for inclusion based
on the criteria. Disagreements were resolved by
discussion between the investigators. The study
flow diagram is shown in Fig. 1.

3

Results

Through systematic analysis, we summarized
the effectiveness of cell therapy in nine studies.
Table 1 shows that a total of 139 patients with
PD were investigated over the 9 studies,
including 2 groups from China, 2 groups from
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Table 1

Overall information of the studies.
PD patients
Study

Leng et al. [12]

Country

China

N
21

Mean age/Age
range (years)
57.33/42–79

Type of study;

Female

Mean duration

follow‐up time

(%)

time (years)

(months)

28.57

–

case series; 7–57

Study design

a prospective , single‐
dose, uncontrolled,
pilot study

Brazzini

Peru

50

62.5/38–81

28.0

9.3

Yin et al. [14]

case series; mean

a prospective, single‐

7.4 ± 4.5, range 1–18 dose, uncontrolled,
pilot study

et al. [13]
China

12

66/52–88

58.33

6.4

case series; 12–36

a prospective, single‐
dose, uncontrolled,
pilot study

Canesi et al. [8]

Italy

5

64.8/60–68

80.0

–

case series; 1–12

Clinical Trials (NCT
01824121)

Venkataramana

India

7

55.4/22–62

0

14.7 ± 7.56

case series; 12–36

a prospective, single‐
dose, uncontrolled,

et al. [9]

pilot study
Freed et al. [10]

USA

40

57/34–75

47.5

14

case series; 36

a prospective, single‐
dose, randomized
controlled, pilot study

Li et al. [11]

Sweden

1

86

0

10

case report; 288

a prospective, uncon‐
trolled, pilot study

Kefalopoulou

England

2

68/67–69

0

11

Case series; 180/216 a prospective, uncon‐
trolled, pilot study

et al. [15]
Kordower

USA

1

61

et al. [7]

America, 1 group from Peru, 1 group from Italy ,
1 group from India, 1 group from Sweden and 1
group from England, i.e., these studies were
distributed throughout Asia, Europe, North
America and South America. The ages of the PD
patients ranged from 22 to 88 years old, and the
mean age distribution was 50–70 years old.
Overall, there are fewer female patients than
males, and many of these patients had an
average disease duration of > 10 years. Study
type and study design of each study and the
follow‐up time are also shown in Table 1.
Table 2 shows the PD treatment options
investigated in the 9 articles, including trans‐
plantation of neural precursor cells, autologous
bone marrow stem cells, retinal pigment

100

22

Case report; 168

a prospective, uncon‐
trolled, pilot study

epithelium (RPE) cells, mesenchymal stem cells
(MSCs), embryonic dopaminergic neurons, and
fetal cells to PD patients. To evaluate the effects
of transplantation, such as tumor formation,
immune rejection, graft‐induced side effects, etc.,
these 9 articles used diagnostic and measurement
tools including magnetic resonance imaging
(MRI), positron emission computed tomography
(PET) and immunohistochemistry.
Several indicators were used to evaluate
efficacy (Table 3). Eight of the studies used the
UPDRS as an effective indicator to evaluate PD
patients. By analyzing the differences in UPDRS
scores before and after transplantation, most of the
articles reported significant reduction in UPDRS
Journal of Neurorestoratology
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Treatment and diagnostic tools.
Study

Leng et al. [12]

Stem cell species
neural precursor

Treatment
local injection

Diagnostic and
MRI, PET‐CT

cells
Brazzini et al. [13]

autologous bone
marrow stem cells

Results

measurement tools
an increase in dopamine release
during the first 6 months

super selective intra‐

MRI, MRS

arterial autologous

mean improvements in NAA/Cr
ratio in both basal ganglia

stem cell implants
Yin et al. [14]

RPE cells

surgical procedure

PET

an increase in dopamine release
during the first 6 months

Canesi et al. [8]
Venkataramana

MSCs
BM‐MSCs

venous implants
surgical procedure

SPECT, PET,

significant positive changes

FP‐CIT, β‐CIT

during the first 6 months

MRI

no significant changes at 12
months

et al. [9]
Freed et al. [10]

nerve cells

surgical procedure

PET

an increase in 18F‐dopa uptake
at 12 months

Li et al. [11]

embryonic

transplantation

Immunohistochem‐

dopaminergic

into the putamen

istry, imaging,

neurons in the grafts and

quantification

complete reinnervation of

neurons

survival of dopaminergic

grafted putamen
Kefalopoulou

fetal cells

et al. [15]

transplantation

PET

an increase in 18F‐dopa uptake

transplantation

Immunohistochem‐

Lewy body‐like pathology in

into the putamen

istry

long‐term nigral grafts

into the putamen

Kordower

dopaminergic

et al. [7]

neurons

RPE, retinal pigment epithelium; MSC, mesenchymal stem cell; BM‐MSC, bone marrow MSC; MRI, magnetic resonance imaging;
PET, positron emission computed tomography; PET‐CT, PET‐computed tomography; MRS, magnetic resonance spectroscopy;
SPECT, single photon emission computed tomography; NAA/Cr, N‐acetylaspartate/creatine.

scores after transplantation: Leng et al. reported
from baseline score of 80.71 ± 15.48 to 72.76 ± 13.31,
7–57 months after transplantation [12];
Brazzini et al. reported from baseline score of 68
and quartile deviations (QD) of 25 to 34 (QD 20),
with a mean follow‐up of 7.4 ± 4.5 months [13];
Yin et al. reported from baseline score of 58.8 ±
27.7/82.9 ± 28.7 to 43.8 ± 23.3/64.0 ± 32.1, 36
months after transplantation with/without
medication [14];
Venkataramana et al. reported from baseline
score of 50.6±15.9/65±22.1 to 31.7/43.3, 12–36
months after transplantation with/without
medication [9].
Four of the articles used Hoehn‐Yahr(HY) scores

to evaluate the patients; similarly, the scores
decreased following transplantation:
Leng et al. reported, from baseline score of 3.71
± 0.94 to 2.86 ± 1.05, 7–57 months after
transplantation [12];
Brazzini et al. reported from baseline score of 3.0
(QD 1.0) to 2.0 (QD 0.5), with a mean follow‐up
of 7.4 ± 4.5 months [13];
Venkataramana et al. reported from baseline
score of 2.785 ± 1.1 to 2.5, 12–36 months after
transplantation [9].
In addition, the Parkinson’s Disease Question‐
naire (PDQ‐39), the Schwab and England
Activities of Daily Living Scale (SE‐ADL),
Northwestern University Disability Scale (NUDS),
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Table 3

Indicators used to evaluate efficacy of transplantation.
Indicators

Study

UPDRS

HY

PDQ‐39

SE‐ADL

Leng et al. [12]

80.71 ± 15.48/

3.71 ± 0.94/

110.62 ± 17.62/

37.14 ± 13.47/

(sores pre‐first

72.76 ± 13.31

2.86 ± 1.05

104.90 ± 17.60

52.38 ± 14.11

68(QD 25)/34(QD 20)

3.0(QD 1.0)/

NUDS
–

PSP
–

surgery/pre‐second
surgery, 7–57months,
on medication)
Brazzini et al. [13]

–

2.0 (QD 0.5)

(baseline/7.4 ± 4.5

70(QD 20)/

16.5(QD

80(QD 10)

9.25)/7.0

months, on medication)
Yin et al. [14]
(baseline/36 months)

–

(QD 7.25)
58.8±27.7/43.8±23.3

–

–

–

–

–

(on medication)
82.9 ± 28.7/64.0 ± 32.1
(off medication)

Canesi et al. [8]

38/44

0.8/0.8

–

–

–

Venkataramana et al. [9] 50.6 ± 15.9/31.7

2.785 ± 1.1/2.5

–

14% improvement

(baseline/12–36 months) (on medication)

(medication not

(12–36 months,

mentioned)

medication not

42/52

(baseline/12 months,
medication not
mentioned)

65 ± 22.1/43.3

Freed et al. [10]

19.5±8.5 (on medication)
58.5±20 (off medication)

Li et al. [11]

–

Kefalopoulou et al. [15]

38/22 (baseline/216

–

mentioned)

(off medication)

(12 months)

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

months, off medication)
23/18 (baseline/180
months, off medication)
Kordower et al. [7]

No on medication score,
an increase in off
medication score

UPDRS, Unified Parkinson’s Disease Rating Scale; HY, Hoehn‐Yahr scores; SE‐SDL, Schwab and England Activities of Daily
Living Scale; NUDS, Northwestern University Disability Scale; PSP, Progressive Supranuclear Palsy Rating Scale.

and Progressive Supranuclear Palsy (PSP)
Rating Scale were also used in some of the
studies to evaluate the efficacy. PDQ‐39 and
NUDS scores decreased slightly following
transplantation, while SE‐ADL scores increased.
Details of the assessment of the safety of the
transplantation in each study are provided in
Table 4. The assessment of tumor formation,
immune rejection, use of immunosuppressants,

graft or delivery induced side effects, illnesses,
sequelae, and death are included. In the 9
investigated studies, no serious adverse events
associated with cell implantation or surgical
procedure developed. One group reported the
sudden death of a patient from a heart attack 4
days after cell implantation, but they have
ruled out the direct relationship with the
implant or implantation procedure [4]. Another
Journal of Neurorestoratology
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Safety evaluation of the procedures.
Projects

Leng et al. [12]

0

Immune rejection
and use of
immunosuppressant
0

Brazzini et al. [13]

–

–

0

0

–

Yin et al. [14]

–

–

–

0

0

1 (sudden heart
attack)
0

Canesi et al. [8]

–

–

–

–

–

–

Venkataramana et al. [9]

–

–

–

–

–

–

Freed et al. [10]

–

–

–

1 (subdural hematoma)

0

0

Li et al. [11]

–

–

–

–

–

–

Kefalopoulou et al. [15]

–

–

–

–

–

–

Kordower et al. [7]

–

–

–

–

–

–

Study

Tumor
formation

Graft or delivery Illnesses or incidents
induced
that required medical Sequelae
side effects
treatment
0
–
–

group described the development of a subdural
hematoma in one of their patients, which was
detected about 6 weeks after surgery and was
“possibly” related to the procedure [5]. In
summary, the transplantation would induce side
effects, but no serious events occurred in the 9
studies that we investigated.

4

Discussion and conclusions

The literature results were obtained by systematic
analysis of 9 valid research papers, which aimed
to evaluate the clinical safety, feasibility and
efficacy of cell transplantation in the treatment
of PD. These studies were carried out in
different countries and regions, and the
populations of the studies also varied. The
researchers used different stem cell types to
treat PD. Leng et al. reported a trial to evaluate
the clinical safety and effectiveness of
transplantation of neural precursor cells in the
treatment for PD [12]. Brazzini et al. evaluated
the feasibility, safety, and effectiveness of
intra‐arterial autologous implantation of adult
stem cells for PD [13]. Yin et al. assessed the
clinical effect of transplantation of human RPE
cells into the unilateral post‐commissural

Death
–

putamen for treatment of PD [14]. Canesi et al.
[8] and Venkataramana et al. [9] reported the
prospective and pilot study of autologous bone
marrow MSCs (BM‐MSCs) unilaterally trans‐
lanted in patients with PD. Li et al. [11],
Kefalopoulou et al. [15] and Kordower et al. [7]
reported the long‐term clinical outcomes of
transplantation of fetal cells or embryonic
dopaminergic neurons in patients with PD.
Across the world, the prevalence of PD
steadily increases with age [6, 16, 17]. Some
researchers suggest a peak around the age of 70
years, with a gradual reduction in prevalence
with increasing age [16]. In this systematic
review, we found that the average age of
patients with PD, who used cell transplantation
as a treatment method, was 50–70 years; the
majority was in their 60s, which is consistent
with previous studies. Many of the patients had
experienced disease durations of > 10 years.
Freed et al. suggested that the transplantation
was beneficial to patients at 60 years old or
younger, but not to older patients [10].
Regardless of the possible interpretation, all
age‐related data must be interpreted. In the
given studies, the population of elderly patients
was commonly small; therefore a few reported

100

cases may have a significant influence on the
results. The analysis of geographical variations
in prevalence is easily confused with demo‐
graphic differences between populations [1].
Our systematic review aimed to investigate the
effects of demographic differences through
age‐specific analysis. By comparing age groups
across regions, we found that fewer PD patients
at the ages of 50–59 years were cured by cell
transplantation in Asia than in North America,
and the number of cured 60–69‐year‐olds in
North America was significantly lower than in
Europe, Asia, and South America.
Based on the 9 articles, we were able to divide
the transplanted stem cells into three categories:
ESCs, MSCs, and brain‐derived neural pro‐
genitor cells (NPCs), which all have the
potential to differentiate into dopaminergic cells.
Different cell types have different transplanta‐
tion methods, but the transplantation method
does not affect the clinical effect of patient. Eight
of the articles used the UDPRS score to evaluate
the patients before and after transplantation, to
determine any improvement in their symptoms.
The results concluded from the 9 studies suggest
that the stem cell transplantation is effective for
the treatment of PD. Since the survival of
DA‐rich cells in the grafted tissue is likely to be
a key factor, and the grafting protocol differs in
several important respects among those clinical
transplantation programs [18], it is difficult to
speculate which of the three types of stem cells
is the most effective. Stem‐cell derived cell
therapy requires more studies to investigate the
safety of stem cell transplantation for PD due to
difficulties in controlling differentiation of
multipotent stem cell and concerns over
tumorigenicity. The diagnostic and post‐
transplant examination tools mainly used
included MRI, magnetic resonance spectroscopy
(MRS), single photon emission computed
tomography (SPECT), PET, immunohistoche‐
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mistry, imaging, and quantification. MRI was
the main diagnostic tool, used in 5 of the 9
articles. MRI can be used to visually determine
whether a patient’s brain tissue is abnormal, and
combining with the UPDRS score, it is effective
to diagnose PD.
By evaluating with UPDRS, HY scores,
PDQ‐39 and SE‐ADL, Leng et al. found that the
symptoms of patients improved after trans‐
plantation [12]. According to the UPDRS, HY
scores, SE‐ADL and NUDS scores, significant
differences were found between baseline and
follow‐up evaluations in the Brazzini group’s
study [13].Yin et al. found improvement in the
primary outcome measure at 3 months post‐
treatment, particularly the UPDRS‐M score in
the off medication [14]. Canesi et al. used
UPDRS and HY scores to assess motor function
in patients 12 months after MSC infusion, and
found mild improvements [8]. Venkataramana
et al. found that patients subjectively reported
marginal improvement in symptoms [9].
Kefalopoulou et al. found that ON periods were
prolonged and the patients’ self‐reported
frequency and severity of motor fluctuations
diminished [15]. Kordower et al. observed that
initially the patient experienced an improve‐
ment in functioning, including UPDRS motor
OFF scores, but that this was followed by
progressive worsening of symptoms [7].
However, Freed et al. found that the UPDRS
scores of younger patients in the transplantation
group had greater improvement than those in
the sham‐surgery group [10]. In summary,
transplantation therapy can improve PD
symptoms; however, comparisons between the
traditional and transplant treatments is
relatively insufficient.
At present, cell therapy for PD is still in its
infancy, and its safety has been questioned. In
our systematic review, none of the 9 articles
included showed significant side effects
Journal of Neurorestoratology
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following transplantation. Leng et al. examined
tumor formation, immune rejection, graft‐
induced side effects, and delivery‐related side
effects following transplantation, and found all
patients behaved normally after transplantation
[12]. In the study reported by Brazzini et al.,
several patients suffered varying degrees of
problem, which were not related to transplan‐
tation, and one died from heart attack [13].
Freed et al. reported a subdural hematoma was
detected about 6 weeks after surgery, which was
thought to be “possibly” related to the surgery,
as the MRI had been normal on the day after
surgery [10]. Kefalopoulou et al. reported two
patients with graft‐induced side effects, but the
influence was insignificant when compared to
the effectiveness of the transplant [15]. Li et al.
reported that post‐mortem autopsy of a PD
patient implanted with dopamine neurons 24
years ago revealed that positive inclusion of
ubiquitin and α‐synuclein was observed in
11%–12% of implanted dopaminergic neurons.
And the clinical benefits induced by transplan‐
tation in this patient were gradually lost 14
years after transplantation [11]. Kordower et al.
also reported a similar phenomenon [7]. Cell
transplantation performed by these two groups
could only improve PD symptoms in a short
term, which was probably because that
implanted cells lost their efficacy during major
degenerative changes and widespread α‐
synucleinopathy development in host brains. In
summary, stem cell therapy for PD is safe, and
the possible graft‐induced side effects are slight
and the advantages outweigh the disadvantages.
Cell transplantation is a potential treatment
option for patients with PD, because of its
satisfactory efficacy and safety. To date, studies
in this field are limited; therefore, more studies
with strict study design, larger sample sizes, and
longer follow‐up are needed to further inves‐
tigate the efficacy and safety.
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